Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial
중국 성인을 대상으로 한 SARS-CoV-2 ARCoV mRNA 백신의 안전성 및 면역원성: 무작위 배정, 이중 맹검, 위약 대조, 1상 시험
Clinical Trial
[키워드] abnormal change
abnormal changes
Academy
administration
adverse event
adverse events
Adverse reaction
Adverse reactions
All participant
All participants
analyses
Analysis
Anti-RBD IgG
anti-SARS-CoV-2
Antibody titre
assigned
baseline
block
Block randomisation
caused
cellular immune responses
China
Chinese
clinical testing
conducted
convalescent patient
Convalescent patients
COVID-19 pandemic
development
domain
dose
dose-escalation
doses
double-blind
effective vaccine
Effective vaccines
eligible participant
ELISA
ELISPOT
ENCODE
enrolled
enzyme
enzyme-linked immunospot
expected
exploratory
Fever
first vaccination
FIVE
foundation
grade 3
group
groups
highest
hospital
humoral
humoral immune responses
Humoral response
humoral responses
IFN-γ
IL-2
immune
immune response
immune responses
immunogenicity
incidence
individual
Intramuscular injection
investigators
Laboratory
laboratory analyses
Laboratory test
Laboratory tests
live SARS-CoV-2
lowest
majority
Medical Science
Medical Sciences
Mild
moderate
mRNA vaccine
natural
neutralisation assays
Neutralising Antibodies
neutralising antibody
observation
outcome
participant
Participants
peaked
Phase 1
phase 1 trial
Placebo
placebo group
placebo-controlled
Primary outcome
pseudovirus
randomised
Randomly
RBD
RBD IgG
RBD-specific IgG
receive
Registered
reported
research and development
resolved
Safe
Safety
safety analyses
safety profile
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2-specific T-cell response
SARS-CoV-2-specific T-cell responses
Science
screened
second dose
second vaccination
secondary outcome
Serious Adverse Event
Serious Adverse Events
Seven
significantly
Specific
Specific T-cell response
Spike protein
Support
systemic adverse event
T-cell Response
T-cell responses
the placebo group
the SARS-CoV-2
titre
titres
Tolerability
treatment allocation
Trial
vaccination
Vaccine
vaccine dose
vaccine doses
were assessed
were given
with COVID-19
Zhejiang
[DOI] 10.1016/S2666-5247(21)00280-9 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1016/S2666-5247(21)00280-9 PMC 바로가기 [Article Type] Clinical Trial